DMK Pharmaceuticals (DMKPQ) has a profit margin of -91.28%, below the Healthcare sector average of 13.89%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2023
Trailing 12 months ending Sep 2023
The latest profit margin for DMKPQ is -91.28% as of September 2023. That compares with 803.94% in the prior-year period — down 111.4% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside DMK Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Over the past year, DMKPQ's profit margin moved from 803.94% to -91.28% — a 111.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in DMK Pharmaceuticals's valuation or profitability profile.
Against Healthcare companies, DMKPQ currently prints -91.28% for profit margin, while the sector average sits near 13.89%. That is roughly 757.2% below the sector mean. Large gaps often invite a closer look at DMK Pharmaceuticals's growth, margins, and balance sheet.
Profit Margin shows how effectively DMK Pharmaceuticals converts resources into returns. At -91.28%, DMKPQ may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 803.94% in the prior-year period — down 111.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting DMKPQ's profit margin (-91.28%), review year-over-year change from 803.94%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.